AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 45.87 |
Market Cap | 1.72B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -3.95 |
PE Ratio (ttm) | -14.66 |
Forward PE | n/a |
Analyst | Buy |
Ask | 59.8 |
Volume | 268,432 |
Avg. Volume (20D) | 320,200 |
Open | 59.20 |
Previous Close | 58.74 |
Day's Range | 57.46 - 60.42 |
52-Week Range | 25.60 - 77.60 |
Beta | undefined |
About IRON
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, M...
Analyst Forecast
According to 10 analyst ratings, the average rating for IRON stock is "Buy." The 12-month stock price forecast is $72.5, which is an increase of 25.19% from the latest price.
7 months ago · seekingalpha.com
Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 ProgressDisc Medicine, Inc. released positive results from the phase 2 AURORA study, using bitopertin for the treatment of patients with EPP and XLP. Potential FDA feedback to initiate a pivotal study using b...